学术探索
学术期刊
学术作者
新闻热点
数据分析
智能评审

特立帕肽治疗老年绝经后骨质疏松症对患者生活质量的影响及安全性评估

被引：6
作者：
陈柏龄
吕中
艾克热木江·木合热木
蒋皓纯
陈志鹏
林玮
袁伟权
机构：
[1] 中山大学附属第一医院脊柱外科广东省骨科学重点实验室
来源：
中国骨科临床与基础研究杂志 | 2018年 / 10卷 / 05期
关键词：
特立帕肽; 骨质疏松,绝经后; 生活质量; 药物副反应;
D O I：
暂无
中图分类号：
R580 [];
学科分类号：
摘要：
目的探讨特立帕肽治疗老年绝经后骨质疏松症对患者生活质量的影响,并进行安全性评估。方法将2015年1月至2016年12月于中山大学附属第一医院接受特立帕肽治疗的35例60岁以上绝经后骨质疏松症患者纳入观察组,同期接受钙剂和维生素D治疗的40例患者纳入对照组。记录并比较用药后3、6个月两组患者在SF-36生活质量评分、Oswestry功能障碍指数(ODI)、视觉模拟量表(VAS)疼痛评分以及药物副反应等方面的差异。结果用药后3、6个月两组患者各疗效指标均较用药前明显改善(P <0.05)。观察组用药后3、6个月患者SF-36评分、VAS评分均明显优于对照组(P <0.05)。用药后3个月观察组ODI低于对照组,但差异无统计学意义(P>0.05);用药后6个月两组比较,差异有统计学意义(P <0.05)。观察组用药后副反应包括头晕、恶心17例,肢体疼痛3例,症状随时间延长而逐渐缓解消失;皮疹、皮肤瘙痒1例,心悸、胸闷2例,双下肢水肿1例,停药后症状缓解消失。结论特立帕肽治疗老年绝经后骨质疏松症短期疗效显著,患者生活质量明显改善,副反应轻微,安全性良好。
引用
收藏
页码：261 / 265
页数：5
相关论文
共 12 条
[1]
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised; open-label; phase 3 trial.[J].Bente L Langdahl;Cesar Libanati;Daria B Crittenden;Michael A Bolognese;Jacques P Brown;Nadia S Daizadeh;Eva Dokoupilova;Klaus Engelke;Joel S Finkelstein;Harry K Genant;Stefan Goemaere;Lars Hyldstrup;Esteban Jodar-Gimeno;Tony M Keaveny;David Kendler;Peter Lakatos;Judy Maddox;Jorge Malouf;Fabio E Massa
[2]
Clinician's Guide to Prevention and Treatment of Osteoporosis [J].
Cosman, F. ;
de Beur, S. J. ;
LeBoff, M. S. ;
Lewiecki, E. M. ;
Tanner, B. ;
Randall, S. ;
Lindsay, R. .
OSTEOPOROSIS INTERNATIONAL, 2014, 25 (10) :2359-2381
[3]
Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: Results from the European Forsteo Observational Study [J].
Rajzbaum, Gerald ;
Grados, Franck ;
Evans, David ;
Liu-Leage, Soyi ;
Petto, Helmut ;
Augendre-Ferrante, Beatrice .
JOINT BONE SPINE, 2014, 81 (01) :69-75
[4]
Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women [J].
Cosman, Felicia ;
Lane, Nancy E. ;
Bolognese, Michael A. ;
Zanchetta, Jose R. ;
Garcia-Hernandez, Pedro A. ;
Sees, Karen ;
Matriano, James A. ;
Gaumer, Kim ;
Daddona, Peter E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (01) :151-158
[5]
Reduction in Fracture Rate and Back Pain and Increased Quality of Life in Postmenopausal Women Treated with Teriparatide: 18-Month Data from the European Forsteo Observational Study (EFOS) [J].
Langdahl, Bente L. ;
Rajzbaum, Gerald ;
Jakob, Franz ;
Karras, Dimitrios ;
Ljunggren, Osten ;
Lems, Willem F. ;
Fahrleitner-Pammer, Astrid ;
Walsh, J. Bernard ;
Barker, Clare ;
Kutahov, Alexey ;
Marin, Fernando .
CALCIFIED TISSUE INTERNATIONAL, 2009, 85 (06) :484-493
[6]
Association of severe vertebral fractures with reduced quality of life - Reduction in the incidence of severe vertebral fractures by teriparatide [J].
Crans, GG ;
Silverman, SL ;
Genant, HK ;
Glass, EV ;
Krege, JH .
ARTHRITIS AND RHEUMATISM, 2004, 50 (12) :4028-4034
[7]
The Oswestry Disability Index [J].
Fairbank, JCT ;
Pynsent, PB .
SPINE, 2000, 25 (22) :2940-2952
[8]
The pain visual analog scale: Is it linear or nonlinear? [J].
Myles, PS ;
Troedel, S ;
Boquest, M ;
Reeves, M .
ANESTHESIA AND ANALGESIA, 1999, 89 (06) :1517-1520
[9]
Quality of life as outcome in the treatment of osteoporosis: The development of a questionnaire for quality of life by the European foundation for osteoporosis [J].
Lips, P ;
Cooper, C ;
Agnusdei, D ;
Caulin, F ;
Egger, P ;
Johnell, O ;
Kanis, JA ;
Liberman, U ;
Minne, H ;
Reeve, J ;
Reginster, JY ;
deVernejoul, MC ;
Wiklund, I .
OSTEOPOROSIS INTERNATIONAL, 1997, 7 (01) :36-38
[10]
中老年女性原发性骨质疏松症危险因素 [J].
蔡科 ;
范占江 .
中国骨质疏松杂志, 2014, 20 (09) :1133-1137
12